Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 12;16(1):82.
doi: 10.1186/s13023-021-01730-7.

Survival outcomes of surgery in patients with pulmonary large-cell neuroendocrine carcinoma: a retrospective single-institution analysis and literature review

Yeye Chen  1 , Jiaqi Zhang  1 , Cheng Huang  1 , Zhenhuan Tian  1 , Xiaoyun Zhou  1 , Chao Guo  1 , Hongsheng Liu  1 , Shanqing Li  2
Affiliations
Review

Survival outcomes of surgery in patients with pulmonary large-cell neuroendocrine carcinoma: a retrospective single-institution analysis and literature review

Yeye Chen et al. Orphanet J Rare Dis. .

Abstract

Background: Pulmonary large-cell neuroendocrine carcinoma (pLCNEC) is a very rare malignancy originating from the lung and bronchus, and its biological behaviour, clinical diagnosis, treatment and prognosis are poorly understood. Thus, the clinical characteristics and surgical treatment-related prognostic factors of this rare disorder must be explored.

Results: The clinical data of 59 patients (48 males and 11 females) who were treated by surgery and diagnosed with pLCNEC by postoperative pathology at Peking Union Medical College Hospital from April 2004 to April 2019 were analysed retrospectively. The median patient age was 62 years (38-79 years), and the median duration of disease was 2 months (0.5-18 months). Compared with other lung malignancies, pLCNEC lacks specific clinical symptoms and imaging features, and preoperative biopsy pathology is often insufficient to confirm the diagnosis. The corresponding numbers of patients who were classified into stages I, II, III and IV according to the postoperative pathological tumour-nodal-metastasis stage were 25, 12, 15 and 7, respectively. The median overall survival was 36 months (0.9-61.1 months). The 1-year, 3-year and 5-year survival rates were 76.3%, 49% and 44.7%, respectively. The tumour stage exerted a significant effect on survival (Cox multivariate analysis p < 0.05).

Conclusions: For patients with resectable pLCNEC, multidisciplinary therapy based on surgery may have good survival benefits, and tumour stage is an independent risk factor for the prognosis of pLCNEC.

Keywords: Prognosis; Pulmonary large-cell neuroendocrine carcinoma; Surgical treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Survival analysis by the Kaplan–Meier method and the survival curve of the whole group. The median OS was 36 months (10.9–61.1 months), and the 1-year, 3-year and 5-year OS rates were 76.3%, 49.0% and 44.7%, respectively
Fig. 2
Fig. 2
Imaging characteristics of peripheral pLCNEC. Chest CT showed a lobulated mass with a clear boundary and obvious short burrs
See this image and copyright information in PMC

References

    1. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB, Jr, Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529–553. doi: 10.1097/00000478-199106000-00003. - DOI - PubMed
    1. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10:1243–1260. doi: 10.1097/JTO.0000000000000630. - DOI - PubMed
    1. Barbareschi M, Mariscotti C, Barberis M, Frigo B, Mosca L. Large cell neuroendocrine carcinoma of the lung. Tumori. 1989;75:583–588. doi: 10.1177/030089168907500614. - DOI - PubMed
    1. Yang Q, Xu Z, Chen X, Zheng L, Yu Y, Zhao X, et al. Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: a large population-based analysis. Thorac Cancer. 2019;10:751–760. doi: 10.1111/1759-7714.12993. - DOI - PMC - PubMed
    1. Eichhorn F, Dienemann H, Muley T, Warth A, Hoffmann H. Predictors of survival after operation among patients with large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg. 2015;99:983–989. doi: 10.1016/j.athoracsur.2014.10.015. - DOI - PubMed

LinkOut - more resources